Clinical reference Biomarker Directory
Back to directory

GH1

Established

GH1/growth hormone testing diagnoses acromegaly or deficiency, though rarely via a single random level.

Also known as GH somatotropin growth hormone
In plain language

Growth hormone regulates growth and metabolism. Because it's released in bursts throughout the day, a single blood test isn't reliable — doctors instead use a more stable related marker (IGF-1) plus special stimulation or suppression tests to properly diagnose too much or too little growth hormone.

Biomarker & context

GH1 encodes growth hormone (somatotropin), a pituitary hormone regulating growth and metabolism; its clinical testing centers on diagnosing either growth hormone excess (acromegaly/gigantism) or deficiency.

What it indicates

Excess GH causes acromegaly in adults or gigantism in children with open growth plates; deficiency causes short stature in children or metabolic/quality-of-life effects in adults.

Diagnosis & clinical testing

Diagnosis of GH excess or deficiency rarely relies on a single random GH level, since GH is secreted in pulses — IGF-1 (a more stable, integrated marker of GH activity over time) and dynamic testing (oral glucose tolerance test for acromegaly, insulin tolerance test for deficiency) are the actual diagnostic standards.

Guiding treatment

Confirmed acromegaly is treated with surgery, medical therapy (somatostatin analogs, GH receptor antagonists), or radiotherapy depending on tumor characteristics; confirmed deficiency may be treated with recombinant GH replacement, particularly in children.

Clinical significance

IGF-1 and dynamic stimulation/suppression testing are the actual diagnostic standards, not isolated GH measurement.

References
  1. General endocrinology reference literature on acromegaly and growth hormone deficiency diagnostic testing standards.